ERBB2 and neoplasm: Several individual trials and meta-analyses showed that a pCR following neoadjuvant chemotherapy improves long-term outcomes in terms of DFS, DDFS, and OS and this was in particular seen in patients with more aggressive tumor types like triple-negative or HER2-positive tumors3–5,22.